argenx (ARGX) Stock Forecast & Price Target

argenx is poised for long-term growth due to its innovative pipeline of antibody-based therapies, led by Vyvgart for gMG and CIDP, with potential future indications for rare autoimmune diseases such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease. The recent failure of a late-stage competitor in CIDP further solidifies argenx's competitive position. The company also has a strong financial outlook, with growing global sales, expanding profit margins, and a pipeline of potential blockbuster drugs in development.

argenx is currently receiving strong sales from their lead product Vyvgart, which is used to treat multiple rare autoimmune disorders. However, with gradual expiration of their patents in the next decade and increased competition from other biopharmaceutical companies, projections for future earnings may be overstated. Additionally, despite positive long-term extension data for efgartigimod, ARGX still faces challenges in obtaining FDA approval for other indications and may have high operating expenses due to ongoing clinical trials and research and development efforts.